Announcements Trials
Browse Landscape

Phase

Phase NA 4Phase 4 4Phase 3 4Phase 2 2Phase EARLY_PHASE1 1Phase 2/3 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 1

Conditions

Polycystic Ovary Syndrome 1Pituitary Neoplasms 1Pituitary ACTH Hypersecretion 1Adrenocortical Hyperfunction 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 901Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 433Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Cabergoline × Clear all
NCT05981742 2023-08-08

Effects of Combined Metformin and Cabergoline in Comparison With Metformin Only Therapy on Ovarian and Hormonal Activities in Iraqi Patients With PCOS

Al-Rasheed University College

Phase 2 Completed
75 enrolled

Polycystic Ovary Syndrome

NCT01915303 2020-09-18

Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease

Novartis

Phase 2 Terminated
68 enrolled 25 charts
Endocrine

Adrenocortical Hyperfunction, Pituitary Neoplasms, Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡